



Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc



Review

Integrative genomics of chronic obstructive pulmonary disease



Brian D. Hobbs, Craig P. Hersh*

Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, United States
 Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, United States
 Harvard Medical School, Boston, MA, United States

ARTICLE INFO

Article history:
 Received 20 June 2014
 Available online 29 July 2014

Keywords:
 Chronic obstructive pulmonary disease
 Genomewide association study
 Genomics
 Network medicine

ABSTRACT

Chronic obstructive pulmonary disease (COPD) is a complex disease with both environmental and genetic determinants, the most important of which is cigarette smoking. There is marked heterogeneity in the development of COPD among persons with similar cigarette smoking histories, which is likely partially explained by genetic variation. Genomic approaches such as genomewide association studies and gene expression studies have been used to discover genes and molecular pathways involved in COPD pathogenesis; however, these “first generation” omics studies have limitations. Integrative genomic studies are emerging which can combine genomic datasets to further examine the molecular underpinnings of COPD. Future research in COPD genetics will likely use network-based approaches to integrate multiple genomic data types in order to model the complex molecular interactions involved in COPD pathogenesis. This article reviews the genomic research to date and offers a vision for the future of integrative genomic research in COPD.

© 2014 Elsevier Inc. All rights reserved.

Contents

1. Introduction	277
2. Genomewide association studies in COPD	278
3. Chromosome 15q25: CHRNA3/CHRNA5/IREB2	278
4. Chromosome 4q31: HHIP	278
5. Chromosome 4q22: FAM13A	278
6. Chromosome 19q13	278
7. Chromosome 14q32: RIN3	279
8. Chromosome 11q22: MMP12	279
9. Chromosome 1q41: TGFB2	279
10. GWAS of pulmonary function	279
11. GWAS of additional COPD phenotypes	279
12. Genomewide gene expression studies in COPD	280
13. COPD gene expression studies in peripheral blood	281
14. MicroRNA profiling in COPD	282
15. Next generation sequencing in COPD	282
16. Integrating genomic data	283
17. Regulation of gene expression	283
18. Integration of genomic and biomarker data in COPD	283
19. Genomic approaches to COPD subtyping	284
20. Summary and future directions	284
Disclosures	284
Acknowledgment	284
References	284

* Corresponding author at: Channing Division of Network Medicine, 181 Longwood Ave., Boston, MA 02115, United States. Fax: +1 617 525 0958.
 E-mail address: craig.hersh@channing.harvard.edu (C.P. Hersh).

1. Introduction

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, accounting for an estimated 3 million deaths in 2010 [1]. COPD is a complex disease with both genetic and environmental determinants, the most important of which is cigarette smoking. However, only a minority of smokers develop COPD, and there is significant variability in lung function across smokers with similar cigarette exposure histories [2]. Some of this heterogeneity in the development of COPD is likely a result of genetic variation. A known genetic risk factor for COPD is severe α_1 -antitrypsin (AAT) deficiency, which is the result of mutations in the SERPINA1 (serpin peptidase inhibitor A1) gene [3,4]. AAT deficiency accounts for approximately 1% of COPD cases and thus is an insufficient genetic factor to account for the heterogeneity in COPD [4].

The complex genetic component of COPD was elucidated through linkage analysis and familial aggregation studies [5]. In previous decades, a series of candidate gene association studies tested genes felt to be important in the COPD pathogenesis. As candidate gene studies by design focused on genes with known potential relationship with COPD pathogenesis, they had no ability to identify novel COPD susceptibility regions. The advent of genome wide association studies (GWAS) allowed for examinations of hundreds of thousands to millions of single nucleotide polymorphisms (SNPs) across the genome. Since 2009, GWAS have revealed replicable statistical associations for COPD. GWAS have also discovered loci related to lung function, emphysema, and other COPD phenotypes (Table 1). Despite the success of GWAS, a large portion of the heritability – the phenotypic variability that is attributable to genetics – remains unexplained [6,7]. “Missing heritability” is not a unique feature for COPD and is a problem across all complex diseases [8]. There are many proposed explanation for the missing heritability in COPD and other diseases, and additional genomic research, including the integration of distinct sources of genomic data, is required.

Silverman and Loscalzo describe three generations of genomics studies (Fig. 1) [9]. First generation studies examine the association between genetic variants and disease phenotype. This concept can be broadened to include any association studies that use a single

Table 1
Phenotypes for COPD genomics studies.

COPD diagnosis
Pulmonary function tests
Spirometry
Forced expiratory volume in 1 s (FEV ₁)
Ratio of FEV ₁ to forced vital capacity
Decline in lung function
Global initiative for chronic obstructive lung disease (GOLD) stages [114]
Stages 1–4, from least to most severe, based on FEV ₁ % predicted
Lung volumes
Diffusing capacity for carbon monoxide
Emphysema on chest computed tomography (CT) scans
Visual assessment
Quantitative image analysis
Emphysema pattern based on local histogram analysis
Airway disease on chest CT scans
Symptoms
Chronic bronchitis
Acute exacerbations
Physiologic impairment
Blood oxygen levels
Exercise capacity
Systemic effects
Body mass index
Co-morbidities
COPD subtypes
COPD-asthma overlap syndrome
Machine learning subtypes

omics technology, e.g., microarray expression profiling. Second generation studies examine associations between two different types of omics data, such as GWAS and gene expression profiling, and aim to correlate the results to disease. Third generation studies utilize multiple omics data types, combined using network methods, and address not only a disease as a whole, but also consider disease subtypes. This article will review the COPD genomics studies to date, which have largely fallen into the first generation category. We will discuss the early progress in integrative genomics studies, which represent the second generation. Future second generation and eventually third generation network medicine studies have the potential to unveil the underlying biology of




Fig. 1. Three generations of genomic studies, described by Silverman and Loscalzo [9]. Figure reproduced with permission.

Download English Version:

<https://daneshyari.com/en/article/10753511>

Download Persian Version:

<https://daneshyari.com/article/10753511>

[Daneshyari.com](https://daneshyari.com)